Indicaciones de los Inhibidores del Sistema Renina–Angiotensina–Aldosterona en Pacientes con COVID-19.

Eduardo Rivas Estany

Texto completo:

PDF

Palabras clave

SARS-CoV-2, Covid-19, Sistema Renina–Angiotensina–Aldosterona, Inhibidores de la enzima convertidora de la angiotensina, Bloqueadores de los receptores de la angiotensina

Referencias

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020;382:1653-9

Li W, Moore MJ, Vasilieva N, Sui J, Wong SK. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426: 450-4.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020(2); 181: 271-80.e8

https://doi.org/10.1016/j.cell.2020.02.052

Sommerstein R, Grani C. Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19. BMJ 2020; 368: m810 (https://www .bmj .com/ content/ 368/ bmj .m810/ rr -2).

Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens 2020 March 11 (Epub ahead of print).

Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 2020 March 18 (Epub ahead of print).

Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z et al. on behalf of the China Hypertension Survey Investigators. Status of hypertension in China: results from the China Hypertension Survey, 2012-2015. Circulation 2018; 137: 2344-56.

doi: 10.1161/CIRCULATIONAHA.117.032380.

Campbell NRC, Zhang X-H. Hypertension in China. Time to Transition From Knowing the Problem to Implementing the Solution. Circulation. 2018;137:2357–9 https://doi.org/10.1161/CIRCULATIONAHA.118.034028

Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1・7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet 2017; 390: 2549-58.

Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111: 2605-10.

https://doi.org/10.1161/CIRCULATIONAHA.104.510461

Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond) 2012; 123: 649-58. DOI: 10.1042/CS20120162

Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 2004; 383: 45-51. DOI: 10.1042/bj20040634

Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612-4. doi:10.1001/jama.2020.4326

NIH Panel Issues Guidelines for COVID-19 Treatment, April 22, 2020, https://covid19treatmentguidelines.nih.gov/ visitado: mayo 2, 2020.

American College of Cardiology. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. 2020. Available at: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. visitado: mayo 2, 2020.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). A Review. JAMA. 2020;323(18):1824-36. doi:10.1001/jama.2020.6019. visitado: mayo 2, 2020.

Enlaces refback

  • No hay ningún enlace refback.




Copyright (c) 2020 Eduardo Rivas Estany

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.